e-learning
resources
Berlin 2008
Wednesday, 08.10.2008
COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease
P. Kaczmarek, K. Sladek, M. Rzeszutko, T. Iwaniec, S. Dziedzina, A. Szczeklik, W. Skucha, A. Undas (Cracow, Proszowice, Poland)
Source:
Annual Congress 2008 - COPD
Session:
COPD
Session type:
E-Communication Session
Number:
4657
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Kaczmarek, K. Sladek, M. Rzeszutko, T. Iwaniec, S. Dziedzina, A. Szczeklik, W. Skucha, A. Undas (Cracow, Proszowice, Poland). Simvastatin does not reduce levels of inflammatory blood markers in patients with stable chronic obstructive pulmonary disease. Eur Respir J 2008; 32: Suppl. 52, 4657
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Thierry Rochat - 07.10.2008 17:09
questions
Did all the patients remain in clinically stable condition during the study period, and how did you assess for this ? An important question about bio-markers is their stability over time when the patient is in stable condition. Do you know something about the coefficient of variability of your different biomarkers ? What does PAOD and IHD mean ?
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Rosuvastatin influence on inflammatory and anti-inflammatory cytokines in blood in patients with chronic obstructive pulmonary disease
Source: International Congress 2017 – COPD management
Year: 2017
Roflumilast significantly decreased inflammatory biomarkers in induced sputum in current smokers patients with severe chronic obstructive pulmonary disease
Source: Annual Congress 2012 - COPD treatment and varia
Year: 2012
Comparison of serum osteopontin levels in patients with exacerbations and stable chronic obstructive pulmonary disease
Source: Annual Congress 2012 - Cell biology, blood and sputum biomarkers in airway diseases
Year: 2012
The value of C-reactive protein as a marker of systemic inflammation in stable chronic obstructive pulmonary disease
Source: Eur Respir J 2007; 30: Suppl. 51, 363s
Year: 2007
Blood MCP-1 levels are increased in chronic obstructive pulmonary disease with prevalent emphysema
Source: International Congress 2018 – Biomarkers of COPD
Year: 2018
Systemic inflammation and increased arterial stiffness in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2006 - COPD and inflammation
Year: 2006
A study of the level of interleukin-32 in induced sputum and plasma of patients with chronic obstructive pulmonary disease and asthma
Source: Annual Congress 2010 - Novel mechanisms in COPD
Year: 2010
Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Relationship between endothelial haemostatic markers in patients with chronic obstructive pulmonary disease
Source: Eur Respir J 2004; 24: Suppl. 48, 61s
Year: 2004
Expression of CD282+/CD284+ on blood granulocytes and its relationship to cytokine status in patients with stable chronic obstructive pulmonary disease
Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations
Year: 2021
Can mean platelet volume be an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease?
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
The effect of inferon on oxygen-dependent metabolism of blood cells in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Basic science in asthma and COPD
Year: 2008
Correlation between endothelial haemostatic markers in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases
Year: 2007
Inferon administration to patients with chronic obstructive pulmonary disease
Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation
Year: 2009
Systemic inflammation in chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 22: 5S-13S
Year: 2003
Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Systemic inflammation in patients with exacerbated chronic obstructive pulmonary disease (COPD): are anaemia of chronic disease and erythropoietin resistance the missing links?
Source: Annual Congress 2007 - Pathophysiology and assessment of COPD
Year: 2007
High interleukin-33 is associated with acute exacerbation in patients with chronic obstructive pulmonary disease
Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases
Year: 2020
Relationship between circulating thrombomodulin levels and latent progression of atherosclerosis in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008
Variability in expression of aquoporine 1 in chronic obstructive pulmonary disease and interstitial lung disease patients
Source: Annual Congress 2009 - What is new in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease?
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept